Pediatric hematopoietic stem cell transplantation

  • Gross T
  • Egeler R
  • Smith F
  • 0


    Mendeley users who have this article in their library.
  • 14


    Citations of this article.


The successful use of allogeneic HSCT for children with malignant and nonmalignant diseases continues to be limited by the development of acute and chronic GVHD, infectious complications, delayed recovery of the immune system, acute and long-term toxicity, and relapse of disease. Significant advances have been made, particularly in the ability to identify suitable sources of HSC. Future advances will depend on a better understanding of the biology of HSC sources, GVHD, immune reconstitution, and common complications. Improved therapies are dependent on participation of children in well-designed, translational and clinical transplant studies.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Thomas G. Gross

  • R. Maarten Egeler

  • Franklin O. Smith

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free